Atrial fibrillation, the most common rhythm disorder, affects more than 10 million people in Europe, with a projected increase from 14 to 17 million by 2030.
It is characterised by irregular and rapid heartbeats. It has a very debilitating effect on the quality of life of those affected. It is primarily responsible for strokes and is a risk factor for heart failure and dementia.
Understanding atrial fibrillation
Atrial fibrillation is manifested by uncontrolled and ineffective contraction of the atrium which promotes the formation of blood clots. It has the effect of accelerating the heart and making it beat irregularly.
Treating atrial fibrillation
Several years ago, Liryc's clinicians identified the sources of atrial fibrillation in the pulmonary veins. This discovery helped to develop a curative treatment for this disorder.
This treatment consists of cauterising the pulmonary veins with a catheter to isolate these sources of arrhythmia. This has become the standard treatment: to date, more than 300,000 patients undergo it each year worldwide.